Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 15/20 | 1.00 |
| ▸ | NOS1 | P29475 | 2/20 | 0.69 |
| ▸ | NOS3 | P29474 | 1/20 | 0.57 |
| ▸ | NOS2 | P35228 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.56 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.56 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5450413 | 0.83 | NOS1 (1.00) | IDO1NOS1NOS3NOS2SLC11A2 | |
| SCHEMBL13007587 | 0.81 | SLC11A2 (0.69) | IDO1NOS1NOS3NOS2SLC11A2 | |
| SCHEMBL14355149 | 0.81 | NOS1 (0.69) | IDO1NOS1NOS3NOS2SLC11A2 | |
| SCHEMBL11451060 | 0.80 | IDO1 (0.67) | IDO1NOS1NOS3NOS2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11778578 | 0.79 | IDO1 (0.69) | IDO1NOS1NOS3NOS2ALDH1A1 | |
| Bromide SCHEMBL5047956 | 0.79 | NOS1 (0.67) | IDO1NOS1NOS3NOS2 | |
| SCHEMBL22275640 | 0.79 | IDO1 (0.65) | IDO1NOS1NOS3NOS2ALDH1A1 | |
| SCHEMBL3771466 | 0.78 | IDO1 (1.00) | IDO1NOS1NOS3NOS2SLC11A2 | |
| Bromide SCHEMBL22262961 | 0.78 | IDO1 (0.63) | IDO1NOS1NOS3NOS2ALDH1A1 | |
| SCHEMBL9612336 | 0.76 | IDO1 (0.61) | IDO1NOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007075177-A2 | ANTIBIOTICS TARGETING MREB | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-07-05 | — | — | WO | claimed |
| US-20060241185-A1 | Antibiotics targeting MreB | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2006-10-26 | — | — | US | claimed |
| US-9656953-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-05-23 | — | — | US | disclosed |
| US-20140221658-A1 | INHIBITION OF CELL PROLIFERATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-08-07 | — | — | US | disclosed |
| US-8642278-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642278-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-02-04 | — | — | US | disclosed |
| US-7855228-B2 | Antibiotics targeting MreB | THE BOARD OF TRUSTEES OF THE LELAND STAMFORD JUNIOR UNIVERSITY (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855228-B2 | Antibiotics targeting MreB | THE BOARD OF TRUSTEES OF THE LELAND STAMFORD JUNIOR UNIVERSITY (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855228-B2 | Antibiotics targeting MreB | THE BOARD OF TRUSTEES OF THE LELAND STAMFORD JUNIOR UNIVERSITY (US) | 2010-12-21 | — | — | US | disclosed |
| US-20070254318-A1 | INHIBITION OF CELL PROLIFERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-01 | — | — | US | disclosed |
| US-20070254318-A1 | INHIBITION OF CELL PROLIFERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-01 | — | — | US | disclosed |
| WO-2007075177-A2 | ANTIBIOTICS TARGETING MREB | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007062222-A2 | INHIBITION OF CELL PROLIFERATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20060241185-A1 | Antibiotics targeting MreB | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2006-10-26 | — | — | US | disclosed |
| US-4208430-A | CARBAMIMIDOTHIOIC ACID PHENYLALKYL ESTERS | SMITHKLINE CORPORATION (US) | 1980-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254318-A1 | INHIBITION OF CELL PROLIFERATION | RB1, RAF1, NRAS | IDO1 4187/4885NOS1 3526/4885NOS3 3705/4885 |
| US-20060241185-A1 | Antibiotics targeting MreB | SMC4, INCENP, DDB1 | IDO1 2985/4885NOS1 4294/4885NOS3 4511/4885 |
| US-20140221658-A1 | INHIBITION OF CELL PROLIFERATION | RB1, RAF1, NRAS | IDO1 4187/4885NOS1 3526/4885NOS3 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.